61881-50-3

Basic information

• Product Name: Propanedioic acid, (4-aminophenyl)methyl-, diethyl ester
• CAS NO: 61881-50-3
• Molecular Formula: C14H19NO4
• Molecular Weight: 265.309
• Mol File: 61881-50-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Propanedioic acid, (4-aminophenyl)methyl-, diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Propanedioic acid, (4-aminophenyl)methyl-, diethyl ester(61881-50-3)
• EPA Substance Registry System: Propanedioic acid, (4-aminophenyl)methyl-, diethyl ester(61881-50-3)

Safety Data

• Hazardous Substances Data: 61881-50-3(Hazardous Substances Data)

Upstream product

• 61881-49-0 Diethyl 2-methyl-2-(4-nitrophenyl)malonate 
• 609-08-5 Diethyl methylmalonate 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 1332487-38-3 3-(4-iodophenyl)-3-methyloxetane 
• 1332491-58-3 2-(4-iodophenyl)-2-methylpropane-1,3-diol 
• 1333468-71-5 2-(4-(4-methylpiperazin-1-yl)phenyl)propanamide 
• 1333468-70-4 2-(4-(4-methylpiperazin-1-yl)phenyl)propanoic acid 
• 1333468-69-1 diethyl 2-methyl-2-(4-(4-methylpiperazin-1-yl)phenyl)malonate 
• 1333468-68-0 diethyl 2-methyl-2-(4-(piperazin-1-yl)phenyl)malonate 
• 138569-22-9 Diethyl 2-methyl-2-<4-(4-trifluoromethyl)-4-hydroxy-2-thiazolin-2-yl)phenyl>malonate 
• 138569-18-3 Diethyl 2-<4-<4-(2,3-dibromopropyl)thiazol-2-yl>phenyl>-2-methylmalonate 
• 138569-21-8 Diethyl 2-<4-(4-carboxythiazol-2-yl)phenyl>-2-methylmalonate 
• 138569-12-7 Diethyl 2-<4-<4-(2-chloroethyl)thiazol-2-yl>phenyl>-2-methylmalonate 
• 139182-94-8 2-[4-(4-Methoxymethyl-thiazol-2-yl)-phenyl]-2-methyl-malonic acid diethyl ester 
• 138569-19-4 Diethyl 2-<4-(4-allylthiazol-2-yl)phenyl>-2-methylmalonate 
• 138569-20-7 Diethyl 2-<4-(4-chloromethylthiazol-2-yl)phenyl>-2-methylmalonate 

Relevant articles and documents

TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION

The present invention relates to compounds defined by formula I wherein the variables R1-R8 are defined as in the description, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of cholesterol ester transfer protein (CETP) and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme.

Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of β-amyloid1-42 secretion

Flurbiprofen, a nonsteroidal antiinflammatory drug (NSAID), has been recently described to selectively inhibit β-amyloid1-42 (Aβ42) secretion, the most toxic component of the senile plaques present in the brain of Alzheimer patients. The use of this NSAID in Alzheimer's disease (AD) is hampered by a significant gastrointestinal toxicity associated with cyclooxygenase (COX) inhibition. New flurbiprofen analogues were synthesized, with the aim of increasing Aβ42 inhibitory potency while removing anti-COX activity. In vitro ADME developability parameters were taken into account in order to identify optimized compounds at an early stage of the project. Appropriate substitution patterns at the alpha position of flurbiprofen allowed for the complete removal of anti-COX activity, while modifications at the terminal phenyl ring resulted in increased inhibitory potency on Aβ42 secretion. In rats, some of the compounds appeared to be well absorbed after oral administration and to penetrate into the central nervous system. Studies in a transgenic mice model of AD showed that selected compounds significantly decreased plasma Aβ42 concentrations. These new flurbiprofen analogues represent potential drug candidates to be developed for the treatment of AD.